Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856545 | 0.93 | F10 (0.54) | F10POLBALDH1A1NPC1RAB9A | |
| SCHEMBL4854194 | 0.91 | F10 (0.63) | F10KCNH2KLKB1NPC1RAB9A | |
| SCHEMBL4858705 | 0.91 | F10 (0.61) | F10KCNH2KLKB1 | |
| SCHEMBL13313049 | 0.89 | F10 (0.67) | F10POLBKCNH2KLKB1 | |
| SCHEMBL4856406 | 0.86 | F10 (0.64) | F10POLBKCNH2ALDH1A1KLKB1 | |
| SCHEMBL4858193 | 0.85 | F10 (0.64) | F10POLBKCNH2ALDH1A1KLKB1 | |
| SCHEMBL4854339 | 0.85 | F10 (0.71) | F10KCNH2ALDH1A1KLKB1 | |
| SCHEMBL4865810 | 0.83 | F10 (0.57) | F10KCNH2KLKB1 | |
| SCHEMBL8355348 | 0.83 | F10 (0.65) | F10POLBKCNH2ALDH1A1KLKB1 | |
| SCHEMBL4857456 | 0.83 | F10 (0.62) | F10KCNH2ALDH1A1KLKB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1456175-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040097491-A1 | Substituted heterocyclic amides | HERRON DAVID KENT (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1307444-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010154-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | F11, SERPINC1, TFPI | F10 15/4885POLB 4142/4885KCNH2 1353/4885 |
| US-20040097491-A1 | Substituted heterocyclic amides | F12, F11, F8 | F10 11/4885POLB 3843/4885KCNH2 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.